Charles Kim, MD
Ophthalmic Plastic and Reconstructive Surgery · Stockton, CANPI 1104242924
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,438 of the $20,612 with a category attached, or 89.5%. Amgen accounts for 98.6% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $9,870, more than ten times the $27 reported in 2019.
Across 57 payments — averaging $361.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$20K
- AbbVie$118
- Optos, Inc.$49
- Merz North America, Inc.$33
- Oyster Point Pharma, Inc.$25
- Carl Zeiss Meditec AG$19
- plus $47 from 3 others
Across 1 payment — averaging $23.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$24
What the payments were for
- Consulting fees$8504%
- Speaking & faculty fees$18,43889%
- Food & beverage$1,2616%
- Gifts$370%
- Entertainment$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 44 | $20,320 |
| AbbVie | 5 | $118 |
| Optos, Inc. | 2 | $49 |
| Merz North America, Inc. | 1 | $33 |
| Oyster Point Pharma, Inc. | 1 | $25 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Alcon | 1 | $18 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Nevro Corp. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$19,556
How this compares
$20,612 in reported general payments places this provider in the 80th percentile of 50 ophthalmic plastic and reconstructive surgery providers in California.
See all ophthalmic plastic and reconstructive surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 46 | $27,003 |
| RestasisCyclosporine | 22 | $19,735 |
| Alphagan PBrimonidine Tartrate | 51 | $16,140 |
| Cyclosporine | 21 | $13,046 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 570 | $5,983 |
| Brimonidine Tartrate | 102 | $5,619 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 23 | $4,381 |
| Latanoprost | 300 | $4,052 |
| Prednisolone Acetate | 64 | $1,894 |
| ErythromycinErythromycin Base | 110 | $1,033 |
| Ketorolac Tromethamine | 91 | $945 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 19 | $699 |
| Timolol Maleate | 80 | $682 |
| Dorzolamide Hcl | 38 | $535 |
| Ofloxacin | 49 | $433 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P | $118 | $62,877119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 50 ophthalmic plastic and reconstructive surgery providers in California.
Other ophthalmic plastic and reconstructive surgery in Stockton
- Marjan FaridIrvine$742K
- Jeffrey JosephNewport Beach$292K
- Sandy Zhang-NunesLos Angeles$149K
- Soheab UgradarLos Angeles$131K
- Andrea KosslerStanford$91K
- Nicolas BiroWest Covina$76K
- Joseph ChangBakersfield$74K
- Anupam JayaramMenlo Park$26K
- Omar OzgurMission Viejo$16K
- Asa MortonSan Diego$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.